Inactive Instrument

Myrexis, Inc. Stock price Other OTC

Equities

MYRX

US62856H1077

Biotechnology & Medical Research

Sales 2012 - Sales 2013 - Capitalization 2.59M
Net income 2012 -31M Net income 2013 -11M EV / Sales 2012 -
Net cash position 2012 89.38 Net cash position 2013 1.21 EV / Sales 2013 -
P/E ratio 2012
-2.21 x
P/E ratio 2013
-0.19 x
Employees -
Yield 2012 *
-
Yield 2013
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 54 13-01-21
Corporate Officer/Principal - 00-12-31
Members of the board TitleAgeSince
Chief Executive Officer 54 13-01-21
More insiders
Myrexi, Inc. is a development-stage company. The Company was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The Company determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The Company operates in pharmaceutical development and related research activities. The Company's revenues were derived from research performed in the United States and, all of the Company's long-lived assets are located in the United States.
More about the company
  1. Stock
  2. Equities
  3. Stock Myrexis, Inc.
  4. Stock Myrexis, Inc. - Other OTC